Kurs & Likviditet
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Magnasense via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
2024-05-08 09:00:00
AegirBio AB, a forefront leader in saliva-based diagnostics solutions, announces today the company has received its inaugural milestone-based payment of USD 148,026 under the RadX NIH program. This milestone validates our unwavering dedication to pioneering research and development.
"At AegirBio, we are committed to pushing the boundaries of innovation and fostering positive change in healthcare. This payment from RadX NIH reflects the tireless efforts of our team," said Marco Witteveen, CEO of AegirBio.
As we celebrate this milestone, our commitment to advancing with RadX remains unwavering. With ongoing support from initiatives like RadX NIH and the expertise of our talented team, we are positioned to drive significant progress and make meaningful contributions to the field.